Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date28 Jan 2018 |
/ Not yet recruitingPhase 4 以安慰剂为对照的麝香通心滴丸治疗冠心病稳定型心绞痛(痰热瘀阻证)的盲法随机平行对照、多中心研究
[Translation] A blind randomized parallel controlled multicenter study of Shexiang Tongxin Dropping Pills in the treatment of stable angina pectoris (phlegm-heat and blood stasis syndrome) in coronary heart disease with placebo as control
通过观察麝香通心滴丸改善冠心病稳定型心绞痛(痰热瘀阻证)患者运动平板的情况,冠心病心绞痛发作次数和发作频率,心绞痛症状的疗效情况,评价麝香通心滴丸治疗冠心病稳定型心绞痛(痰热瘀阻证)的有效性和安全性。
[Translation] To evaluate the effectiveness and safety of Musk Tongxin Dropping Pills in treating stable angina pectoris (phlegm-heat and blood stasis syndrome) of coronary heart disease by observing the effects of Musk Tongxin Dropping Pills on improving treadmill exercise, the number and frequency of angina attacks, and angina symptoms in patients with stable angina pectoris (phlegm-heat and blood stasis syndrome) of coronary heart disease.
100 Clinical Results associated with Neimenggu Kangenbei Pharmaceutical Co. Ltd. Hangjinqi Shenglon
0 Patents (Medical) associated with Neimenggu Kangenbei Pharmaceutical Co. Ltd. Hangjinqi Shenglon
100 Deals associated with Neimenggu Kangenbei Pharmaceutical Co. Ltd. Hangjinqi Shenglon
100 Translational Medicine associated with Neimenggu Kangenbei Pharmaceutical Co. Ltd. Hangjinqi Shenglon